Basic Search  |  Summaries  |  Advanced Search

Violation Tracker Individual Record

Company: King Pharmaceuticals LLC
Current Parent Company: Pfizer
Penalty: $36,500,000
Year: 2014
Date: September 9, 2014
Offense Group: competition-related offenses
Primary Offense: price-fixing or anti-competitive practices
Secondary Offense: generic drug pay for delay
Mega-Scandal: Generic Drug Pay for Delay
Violation Description: King Pharmaceuticals and Mutual Pharmaceutical Company together agreed to pay $73 million to direct purchaser plaintiffs to settle litigation alleging they were part of a scheme to delay the introduction of a generic alternative to the muscle relaxant Skelaxin. Court documents did not specify how much each company would pay. Here we assume they each paid half of the total.
Level of Government: federal
Action Type: private litigation
Court: Eastern District of Tennessee
Civil or Criminal Case: civil
Case ID: 1:12md2343
Case Name: Skelaxin (Metaxalone) Antitrust Litigation
Private Lawsuit Resolution Type: settlement
HQ Country of Current Parent: USA
HQ State of Current Parent: New York
Ownership Structure of Current Parent: publicly traded
Major Industry of Current Parent: pharmaceuticals
Specific Industry of Current Parent: pharmaceuticals
Source of Data: (click here)
Link to PACER Case Docket (must be logged in): (click here)
Link to Archived Court Document:  subscribe to see this data field
Source Notes: If an online information source is not working, check the Violation Tracker Data Sources page for an updated link.
Current parent company note: Parent-subsidiary relationship is current as of the most recent revision listed in the Update Log.